No Data
No Data
Express News | 4,000TH Firefighter Undergoes Lucid Diagnostics' Esoguard® Esophageal Precancer Testing
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Lowers Price Target to $7.5
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics with a Buy and lowers the price target from $8 to $7.5.
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $7.5
Ascendiant analyst Edward Woo maintains $Lucid Diagnostics(LUCD.US)$ with a buy rating, and adjusts the target price from $8 to $7.5.According to TipRanks data, the analyst has a success rate of 34.7%
Express News | Lucid Diagnostics Inc : Ascendiant Capital Markets Cuts Target Price to $7.5 From $8
Express News | Lucid Diagnostics Inc - Determined to Reschedule 2024 Annual Meeting of Stockholders for 11:00 A.m. Eastern Time on July 23
No Data